Because the digestive system can break down medications before theyre absorbed, oral semaglutide has special instructions
Given the high rate of gastrointestinal tolerability challenges and resultant discontinuation that is characteristic of GLP-1 therapy, we believe that a personalized approach to GLP-1 titration and dosing, including a mealtime bolus option, would give patients an opportunity to reach their treatment goals, while experiencing easier therapy initiation and a more tolerable maintenance regimen, said Jeb Besser, CEO of Modular Medical.
For the scenario of "Strongest Current Evidence," research data suggests CagriSema may be more relevant
Although SUs have been linked to DR progression [9, 49], long-term SU use has demonstrated a reduction in DR risk over 6 to 10 years [54, 87], with each year of SU therapy associated with a 7% decrease in DR risk [87]